@Article{or.2022.03536,
AUTHOR = {ZHEN JIA, ZHENGTING QIAN, YONG TANG, XIANG LI, YAN SHI, HENG XIN, YOUWU FAN, HEMING WU},
TITLE = {LncRNA WEE2-AS1 knockdown inhibits the proliferation, migration and invasion of glioma cells via regulating miR-29b-2- 5p/TPM3 axis},
JOURNAL = {Oncology Research},
VOLUME = {29},
YEAR = {2021},
NUMBER = {2},
PAGES = {105--117},
URL = {http://www.techscience.com/or/v29n2/48800},
ISSN = {1555-3906},
ABSTRACT = {Glioma is a general malignant tumor with a dismal prognosis. Long noncoding RNAs (lncRNAs) have been
implicated in the initiation and processes of tumors. An investigation of the GEPIA database revealed that long
noncoding RNA WEE2 antisense RNA 1 (WEE2-AS1) is upregulated in glioma tissues compared to normal brain
tissues, and validation with quantitative real-time polymerase chain reaction (qRT–PCR) revealed that WEE2-AS1
expression was consistent with the database prediction. Fluorescence in situ hybridization (FISH) assays revealed that
WEE2-AS1 was localized primarily in the cytoplasm. Clone formation experiment and EDU assay were used to detect
cell proliferation ability, and Transwell assay was used to detect cell migration and invasion ability, Western-blot
assay and immunofluorescence were used to determine TPM3 protein level. Functional experiments revealed that the
downregulation of WEE2-AS1 impeded cell proliferation, migration, and invasion in glioma cell lines. Furthermore,
downregulation of WEE2-AS1 suppressed tumor growth in vivo. Bioinformatics predictions and integrated
experiments indicated that WEE2-AS1 promoted tropomyosin 3 (TPM3) expression by sponging miR-29b-2-5p. A
dual-luciferase reporter assay was conducted to uncover the binding of WEE2-AS1 and miR-29b-2-5p and that of
miR-29b-2-5p and TPM3. Additionally, a series of rescue assays showed that WEE2-AS1 promotes proliferation,
migration, and invasion by targeting miR-29b-2-5p to regulate TPM3 expression. Ultimately, the results of this study
indicate that WEE2-AS1 plays an oncogenic role in glioma and may promote further investigations of the diagnostic
and prognostic value of WEE2-AS1 in glioma.},
DOI = {10.32604/or.2022.03536}
}